Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

In confirmation hearings for his nomination as secretary of the Department of Health and Human Services, the focus was on domestic issues. The agency has a vast global scope as well.

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Compared to the people who got a placebo, those who received Ozempic said they drank fewer drinks at home. They also drank ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

Now, researchers in a lab at the University of Minnesota, using a drug called CD200AR-L, have developed their own vaccine to ...

(ABC 6 News) — A new vaccine is being tested in the battle against childhood brain cancer. Researchers at the University of ...

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.